All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA2022 abstracts: What's hot in multiple myeloma?

By Marta Llobet-Canela,Becky Gribbell,Ella Dixon

Share:

Featured:

Paul RichardsonPaul RichardsonElena ZamagniElena ZamagniHermann EinseleHermann EinseleHeinz LudwigHeinz LudwigSonja ZweegmanSonja ZweegmanMiles PrinceMiles PrinceSagar LonialSagar LonialMaría-Victoria MateosMaría-Victoria Mateos

Jun 6, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Newly diagnosed multiple myeloma

LB2366

Phase 3 DETERMINATION trial in newly diagnosed multiple myeloma: lenalidomide, bortezomib and dexamethasone (RVD) ± autologous stem cell transplantation and lenalidomide maintenance to progression

S175

ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

S176

Daratumumab, carfilzomib, lenalidomide, and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04

S178

Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology

S179

Randomized comparison between KRd and KTd induction, followed by K maintenance or observation in transplant non-eligible patients with NDMM (AGMT-MM02 trial)

Relapsed/refractory multiple myeloma

S103

Efficacy and safety of ARI0002H, an academic BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in patients with relapsed/refractory multiple myeloma

S184

Evaluating teclistamab in patients with relapsed/ refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents

S185

CARTITUDE-2 Cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy

S188

Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: Updated phase 1b results

S263

Phase I open-label single arm study of GPRC5D CAR-T cells (ORICAR-017) In patients with relapsed/refractory multiple myeloma (POLARIS)

P1463

Phase I dose escalation of LAVA-051, a novel bispecific gamma-delta T-cell engager (GAMMABODY™), in relapsed/refractory hematological malignancies

Other

S244

Effect of anti-spike neutralizing monoclonal antibodies on COVID-19 progression and time to viral clearance in patients with hematological malignancies and SARS-COV-2 infection: The GIMEMA experience

P914

Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: A phase 2 study by the European Myeloma Network

EHA2022 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022AL amyloidosisHigh-riskTeclistamabCOVID-19LenalidomideBelantamab mafodotinCarfilzomibRelapsed/refractory multiple myelomaNewly diagnosed multiple myelomaDaratumumabCiltacabtagene autoleucelBCMA CAR-T CAR therapyT-cell engagersCARTITUDE-2

Your opinion matters

Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?

Newsletter

Subscribe to get the best content delivered to your inbox